MAM
ELDN icon

Meeder Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Meeder Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-141
Closed -$3K – 2169
2019
Q2 		$3K Buy
141
+87
+161% +$3.81K ﹤0.01% 1789
2019
Q1 		$4K Sell
54
-14
-21% -$929 ﹤0.01% 1433
2018
Q4 		$2K Buy
68
+8
+13% +$510 ﹤0.01% 1569
2018
Q3 		$5K Buy
60
+30
+100% +$3.06K ﹤0.01% 1324
2018
Q2 		$3.74K Sell
30
-12
-29% -$1.24K ﹤0.01% 1323
2018
Q1 		$4K Sell
42
-18
-30% -$1.33K ﹤0.01% 1272
2017
Q4 		$4K Buy
60
+10
+20% +$755 ﹤0.01% 1356
2017
Q3 		$5K Hold
50
– – ﹤0.01% 1259
2017
Q2 		$5K Buy
50
+30
+150% +$3.06K ﹤0.01% 1187
2017
Q1 		$3K Sell
20
-33
-62% -$4.85K ﹤0.01% 1251
2016
Q4 		$8K Buy
+53
New +$10.2K ﹤0.01% 794

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's ELDN Position: Q3 2019 in Review

Meeder Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2019, closing a stake of 141 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in ELDN in Q4 2016 and held it in 11 quarters. The position peaked at $8K in Q4 2016. 15 funds tracked by Wall St. Rank hold ELDN as of Q3 2019.

  • Meeder Asset Management reported no remaining Eledon Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Meeder Asset Management sold 141 Eledon Pharmaceuticals shares in Q3 2019, an estimated $3K.
  • Meeder Asset Management first reported a position in Eledon Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Meeder Asset Management's Eledon Pharmaceuticals position peaked at $8K in Q4 2016.
  • 15 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2019.

Based on Meeder Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.